Free Trial

Johnson & Johnson (JNJ) Stock Price, News & Analysis

Johnson & Johnson logo
$274.31 +8.14 (+3.06%)
As of 12:46 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Johnson & Johnson Stock (NYSE:JNJ)

Advanced

Key Stats

Today's Range
$267.67
▼
$274.09
50-Day Range
$248.90
▼
$278.66
52-Week Range
$185.12
▼
$282.02
Volume
4.01 million shs
Average Volume
7.94 million shs
Market Capitalization
$660.35 billion
P/E Ratio
41.63
Dividend Yield
1.95%
Price Target
$275.92
Consensus Rating
Moderate Buy

Company Overview

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions. MedTech provides medical devices and technologies used in surgery, orthopaedics, cardiovascular care, vision care and other healthcare settings.

The company’s portfolio includes prescription medicines and medical-device brands such as DARZALEX, STELARA, ERLEADA, ETHICON, DePuy Synthes, Biosense Webster and Cerenovus. In 2023, Johnson & Johnson completed the separation of its consumer-health business, which now operates as Kenvue. Joaquin Duato serves as Johnson & Johnson’s chairman and chief executive officer.

AI Generated. May Contain Errors.

Johnson & Johnson Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
80th Percentile Overall Score

JNJ MarketRank™: 
4.02497662615 of 5 stars

Johnson & Johnson scored higher than 80% of companies evaluated by MarketBeat, and ranked 79th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Johnson & Johnson has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 1 strong buy rating, 17 buy ratings, 8 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for Johnson & Johnson is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Johnson & Johnson has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Johnson & Johnson's stock forecast and price target.
  • Earnings Growth

    Earnings for Johnson & Johnson are expected to grow by 3.87% in the coming year, from $11.12 to $11.55 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Johnson & Johnson is 41.51, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.16.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Johnson & Johnson is 41.51, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.36.

  • Price to Earnings Growth Ratio

    Johnson & Johnson has a PEG Ratio of 2.67. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Johnson & Johnson has a P/B Ratio of 8.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Johnson & Johnson's valuation and earnings.
  • Percentage of Shares Shorted

    0.70% of the float of Johnson & Johnson has been sold short.
  • Short Interest Ratio / Days to Cover

    Johnson & Johnson has a short interest ratio ("days to cover") of 1.97, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Johnson & Johnson has recently decreased by 24.03%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Johnson & Johnson pays a meaningful dividend of 1.98%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Johnson & Johnson has been increasing its dividend for 64 years.

  • Dividend Coverage

    The dividend payout ratio of Johnson & Johnson is 81.21%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 46.41% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.

  • Read more about Johnson & Johnson's dividend.
  • News Sentiment

    Johnson & Johnson has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 78 news articles for Johnson & Johnson this week, compared to 10 articles on an average week.
  • Search Interest

    115 people have searched for JNJ on MarketBeat in the last 30 days. This is an increase of 72% compared to the previous 30 days.
  • MarketBeat Follows

    59 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is an increase of 48% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Johnson & Johnson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,271,766.00 in company stock.

  • Percentage Held by Insiders

    0.16% of the stock of Johnson & Johnson is held by insiders.

  • Percentage Held by Institutions

    69.55% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Johnson & Johnson's insider trading history.
Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JNJ Stock News Headlines

Elon Musk about to bankrupt Amazon, Microsoft & Google?
Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracking a new Elon Musk project he calls the most epic AI initiative in history. The plan could give Musk access to 50 times more computing power than the rest of the world combined, a development Brown says is drawing attention from executives at Amazon, Microsoft, and Google. Brown compares the scale of this project to the SpaceX IPO, which minted thousands of millionaires overnight.tc pixel
Teradyne, Grail and Fabrinet Lead 5 Growth Stocks Now Priced Like Value Plays
5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps (JNJ)
Teradyne, Grail, Kratos Defense, FormFactor and Fabrinet have pulled back despite strong growth, setting up potential entry points in robotics, quantum and AI.
Modern clinical lab with a microscope on a clean bench, suggesting AstraZeneca oncology research and drug pipeline.
What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs (JNJ)
Polls suggest a divided government after the midterms, a scenario that historically benefits healthcare stocks. Here's how the XLV and IHF ETFs compare for investors eyeing the sector.
A laptop displaying an upward-trending multi-line stock chart sits on a wooden desk beside a coffee mug and smartphone.
MarketBeat Week in Review – 10/12 - 10/16 (JNJ)
Tech stocks fell on inflation fears and AI infrastructure concerns while the Dow rose, as MarketBeat analysts review earnings outlooks, sector rotation, and stock picks from the week's top stories.
Johnson & Johnson logo displayed in a laboratory setting with vials, a microscope, and researchers in the background.
Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
Johnson & Johnson posted Q3 revenue growth of 5.9% to $25.4 billion, raised guidance, and gained analyst support as its OTTAVA surgical system and talc settlement shape its long-term outlook.
See More Headlines

JNJ Stock Analysis - Frequently Asked Questions

Johnson & Johnson's stock was trading at $207.07 at the beginning of 2026. Since then, JNJ shares have increased by 32.3% and is now trading at $273.8940.

Johnson & Johnson (NYSE:JNJ) issued its earnings results on Tuesday, October, 13th. The company reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson's quarterly revenue was up 5.9% on a year-over-year basis.
Read the conference call transcript
.

Johnson & Johnson subsidiaries include these companies: Momenta Pharmaceuticals, TARIS Biomedical, Verb Surgical, Auris Health, Ci:z Holdings, Zarbee's Naturals, Orthotaxy, and more.

Johnson & Johnson's top institutional shareholders include Ninety One UK Ltd (0.27%), Sumitomo Mitsui Trust Group Inc. (0.23%), Assenagon Asset Management S.A. (0.12%) and Bank Julius Baer & Co. Ltd Zurich (0.12%). Insiders that own company stock include & Johnson Johnson, Jennifer L Taubert, Kathryn E Wengel, Timothy Schmid, Vanessa Broadhurst, Robert J Decker, Elizabeth Forminard and Mark A Weinberger.
View institutional ownership trends
.

Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Johnson & Johnson investors own include NVIDIA (NVDA), Pfizer (PFE), JPMorgan Chase & Co. (JPM), AbbVie (ABBV), Walmart (WMT), Procter & Gamble (PG) and AT&T (T).

Company Calendar

Record date for 9/8 Dividend
8/25/2026
Ex-Dividend for 9/8 Dividend
8/25/2026
Dividend Payable
9/08/2026
Last Earnings
10/13/2026
Today
11/04/2026
Record date for 12/8 Dividend
11/24/2026
Ex-Dividend for 12/8 Dividend
11/24/2026
Dividend Payable
12/08/2026
Investor update
12/08/2026
Fiscal Year End
12/31/2026
Next Earnings (Estimated)
1/20/2027

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:JNJ
CIK
200406
Employees
138,200
Year Founded
1886

Price Target and Rating

High Price Target
$320.00
Low Price Target
$210.00
Potential Upside/Downside
+0.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
26 Analysts

Profitability

EPS (Trailing Twelve Months)
$6.60
Trailing P/E Ratio
41.47
Forward P/E Ratio
23.71
P/E Growth
2.67
Net Income
$26.80 billion
Net Margins
16.20%
Pretax Margin
17.86%
Return on Equity
31.64%
Return on Assets
13.04%

Debt

Debt-to-Equity Ratio
0.44
Current Ratio
1.02
Quick Ratio
0.74

Sales & Book Value

Annual Sales
$94.19 billion
Price / Sales
7.00
Cash Flow
$14.29 per share
Price / Cash Flow
19.16
Book Value
$33.87 per share
Price / Book
8.08

Miscellaneous

Outstanding Shares
2,407,310,000
Free Float
2,403,458,000
Market Cap
$659.20 billion
Optionable
Optionable
Beta
0.22

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NYSE:JNJ) was last updated on 11/4/2026 by MarketBeat.com Staff.
From Our Partners